Sort
51,593 grants matching “hepatitis”
Multi-Omics Characterization of Plasmodium Vivax Hypnozoites
$688,160David Serre · University Of Maryland Baltimore · R01 · FY2025 · AI
CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv
$688,135Frederick Oliver Cope · Navidea Biopharmaceuticals, Inc. · R44 · FY2016 · CA
Characterizing the Epigenetic relationship between aging, HIV-infection, ART and biological outcomes
$687,918Beth D. Jamieson-Karavodin · University Of California Los Angeles · R01 · FY2020 · AG
Rhesus HHV-8 homologue in AIDS-related malignancies
$687,883Scott W Wong · Oregon Health & Science University · R01 · FY2024 · CA
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia
$687,791Anastasia Khvorova · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · HD
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs
$687,760David L Thomas · Johns Hopkins University · R01 · FY2022 · DA
Development of Natural Product Leads as Anticancer Therapeutics
$687,723John Beutler · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Association between pre-diagnosis hepatic fat infiltration and risk of liver metastasis and mortality in a large cohort of stage I-III colorectal cancer survivors
$687,694Edward Giovannucci · Harvard University D/B/A Harvard School Of Public Health · R01 · FY2025 · CA
Understanding and Targeting Transcriptional Master Regulators in Hepatocellular Carcinoma
$687,679Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2025 · CA
HCV-specific T cell response
$687,583Christopher M. Walker · Research Inst Nationwide Children'S Hosp · R37 · FY2013 · AI
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs
$687,581David L Thomas · Johns Hopkins University · R01 · FY2023 · DA
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
$687,555Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2013 · AI
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)
$687,523Charles W. Flexner · Johns Hopkins University · R24 · FY2022 · AI
The Progression of Hepatitis C Among IDUs with HIV
$687,429Ashwin Balagopal · Johns Hopkins University · R01 · FY2016 · DA
Repurposing Siponimod for Alzheimer's Disease
$687,290Marwan Noel Sabbagh · St. Joseph'S Hospital And Medical Center · R01 · FY2023 · AG
Neurodegeneration and Brain Function in Aging with HIV and Parkinson's Disease
$687,174Tilman Schulte · Sri International · R01 · FY2014 · AA
Longitudinal Study of Early NAFLD Progression and the Gut Microbiome in Asian Americans, Native Hawaiians and Whites
$687,172Unhee Lim · University Of Hawaii At Manoa · R01 · FY2023 · MD
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
$687,160Luc Teyton · Scripps Research Institute, The · U01 · FY2024 · AI
Paneth cells-derived IL-17A and liver ischemia reperfusion injury
$687,146H. Thomas Lee · Columbia University Health Sciences · R01 · FY2022 · DK
Novel Targets for Reducing Atherosclerosis in Type 1 Diabetes
$687,026Sudha B Biddinger · Boston Children'S Hospital · R01 · FY2022 · HL
Viral Hepatitis, Early Ed. & Linkage to Care for Persons w/Chronic HBV & HCV
$686,985William Nazareth · Community Health Project, Inc. · U51 · FY2013 · PS
Ex-vivo bioengineered technology to unravel dysfunction due to non-alcoholic steatohepatitis (NASH)
$686,972Jason A Wertheim · University Of Arizona · R01 · FY2025 · DK
Working with HIV clinics to adopt addiction treatments using Implementation Facilitation (WHAT IF?)
$686,932David Fiellin · Yale University · R01 · FY2016 · DA
PROTEOMICS CORE
$686,824Richard Daniel Carliss · University Of Washington · P30 · FY2010 · DA
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression
$686,752Joseph Avruch · Massachusetts General Hospital · R01 · FY2010 · CA